Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial

Sandro Pignata(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), I. L. Ray-Coquard(Centre Léon Bérard), Simona Frezzini(Istituti di Ricovero e Cura a Carattere Scientifico), Saverio Cinieri(Ospedale A. Perrino), Florence Joly(Centre François Baclesse), Ciro Gallo(University of Campania "Luigi Vanvitelli"), C. Dubot(Institut Curie), Elena Zafarana(Nuovo Ospedale di Prato), Nicoletta Colombo(University of Milano-Bicocca), Giovanni Scambia(Agostino Gemelli University Polyclinic), Michele Orditura(University of Campania "Luigi Vanvitelli"), Carmela Pisano(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vanda Salutari(Agostino Gemelli University Polyclinic), Angiolo Gadducci(University of Pisa), Aristotelis Bamias(National and Kapodistrian University of Athens), Enrico Breda(Fatebenefratelli Hospital), Daniela Sambataro(Ospedale Garibaldi), Antonio Ardizzoia(Alessandro Manzoni Hospital), Coraline Dubot(Institut Curie), Domenica Lorusso(Agostino Gemelli University Polyclinic), Frédèric Selle, Serafina Mammoliti(Ospedale Policlinico San Martino), Patricia Pautier(Université Paris-Saclay), Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Isabelle Ray‐Coquard(Centre Léon Bérard), Gennaro Daniele(Università Cattolica del Sacro Cuore), Rossella Lauria, Cristiana Sessa(Institute of Oncology Research), Francesco Perrone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Nicoletta Colombo(University of Milano-Bicocca), Emmanuel Guardiola(Centre Hospitalier de la Dracénie), Rémy Largillier(Centre Azuréen de Cancérologie), Francesco Raspagliesi(Fondazione IRCCS Istituto Nazionale dei Tumori), Laure Favier(Hôpital privé du Confluent), Alessandra Bologna(Azienda Sanitaria Unità Locale di Reggio Emilia)
The Lancet Oncology
February 1, 2021
10.1016/s1470-2045(20)30637-9
Cited by 148

Related Papers

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2017|1.4k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2013|1.1k